2025-03-12 13:06:58
Latest Post
W S Industries India Ltd's subsidiary to acquire 54.89 acres land for Rs. 46.66 crores
IKS Health wins Top Honors in 2025 Black Book Survey in New AI-Driven RCM Category
Mipco Seamless Rings Gujarat Ltd approves shifting of registered office
Crizac Limited gets Sebi Nod for Rs 1,000 cr IPO
REC Limited inaugurates REC Experience Center
Stock Report
Suven Life Sciences Ltd reports consolidated loss of Rs. 12.68 crores in Q2 FY2024
Posted On : 2023-11-05 16:12:00( TIMEZONE : IST )
Suven Life Sciences Limited has reported Consolidated financial results for the period ended September 30, 2023.
Financial Results (Q2 FY2024) - QoQ Comparison
The company has reported total income of Rs. 8.2013 crores during the period ended September 30, 2023 as compared to Rs. 9.4369 crores during the period ended June 30, 2023.
The company has posted net profit / (loss) of Rs. -12.6802 crores for the period ended September 30, 2023 as against net profit / (loss) of Rs. -24.0905 crores for the period ended June 30, 2023.
The company has reported EPS of Rs. -0.58 for the period ended September 30, 2023 as compared to Rs. -1.10 for the period ended June 30, 2023.
| Financials | Q2 FY2024 | Q1 FY2024 | % Change |
| Total Income | ₹ 8.2013 crs | ₹9.4369 crs |  -13.09% |
| Net Profit | ₹-12.6802 crs | ₹-24.0905 crs |  47.36% |
| EPS | ₹-0.58 | ₹-1.10 | 47.27% |
Financial Results (Q2 FY2024) - YoY Comparison
The company has reported total income of Rs. 8.2013 crores during the period ended September 30, 2023 as compared to Rs.4.5926 crores during the period ended September 30, 2022.
The company has posted net profit / (loss) of Rs.-12.6802 crores for the period ended September 30, 2023 as against net profit / (loss) of Rs.-23.1815 crores for the period ended September 30, 2022.
The company has reported EPS of Rs.-0.58 for the period ended September 30, 2023 as compared to Rs.-1.59 for the period ended September 30, 2022.
| Financials | Q2 FY2024 | Q2 FY2023 | % Change |
| Total Income | ₹ 8.2013 crs | ₹4.5926 crs |  78.58% |
| Net Profit | ₹-12.6802 crs | ₹-23.1815 crs | 45.30% |
| EPS | ₹-0.58 | ₹-1.59 | 63.52% |
Financial Results (Half Year Ended FY2024) - YoY Comparison
The company has reported total income of Rs.17.6382 crores during the 6 Months period ended September 30, 2023 as compared to Rs.8.5676 crores during the 6 Months period ended September 30, 2022.
The company has posted net profit / (loss) of Rs.-36.7707 crores for the 6 Months period ended September 30, 2023 as against net profit / (loss) of Rs.-39.5077 crores for the 6 Months period ended September 30, 2022.
The company has reported EPS of Rs.-1.69 for the 6 Months period ended September 30, 2023 as compared to Rs.-2.72 for the 6 Months period ended September 30, 2022.
| Financials | Half Year Ended FY2024 | Half Year Ended FY2023 | % Change |
| Total Income | ₹17.6382 crs | ₹8.5676 crs | 105.87% |
| Net Profit | ₹-36.7707 crs | ₹-39.5077 crs | 6.93% |
| EPS | ₹-1.69 | ₹-2.72 | 37.87% |
Shares of Suven Life Sciences Limited was last trading in BSE at Rs. 78.31 as compared to the previous close of Rs. 76.17. The total number of shares traded during the day was 44914 in over 519 trades.
The stock hit an intraday high of Rs. 79.74 and intraday low of 75.74. The net turnover during the day was Rs. 3461616.00.
